Clinical Trials Logo

Influenza clinical trials

View clinical trials related to Influenza.

Filter by:

NCT ID: NCT03076385 Active, not recruiting - Influenza Clinical Trials

Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects

Start date: December 2015
Phase: Phase 1
Study type: Interventional

This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.

NCT ID: NCT03068949 Recruiting - Influenza Clinical Trials

Comparison of Three Licensed Influenza Vaccines

Start date: October 28, 2015
Phase: Phase 4
Study type: Interventional

This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.

NCT ID: NCT03061955 Active, not recruiting - Influenza Clinical Trials

Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

Start date: October 1, 2016
Phase: N/A
Study type: Observational

The objective of this study is to evaluate the safety and efficacy of concurrent administration of influenza vaccine in patients receiving anti-PD1 immunotherapy (nivolumab or pembrolizumab). This will be a prospective observational study, aiming to assess patient tolerance of treatment, adverse events (incidence, grade, need for hospitalization), incidence of influenza infections, and seroconversion rates.

NCT ID: NCT03058692 Not yet recruiting - Influenza Clinical Trials

Two Doses of Multimeric-001 (M-001) Followed by Two Doses of an Influenza A/H7N9 Vaccine

Start date: n/a
Phase: Phase 2
Study type: Interventional

This is a Phase II randomized, double-blind, placebo-controlled trial in 240 males and non-pregnant females, 18 to 45 years old, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of two priming doses of M-001 followed by boosting with two doses of MF59-adjuvanted or non-adjuvanted monovalent influenza A/H7N9 IIV. The monovalent influenza A/H7N9 IIV was derived from the HA of the influenza A/Shanghai/2/2013 (H7N9) virus. Primary objectives: To assess the safety and reactogenicity of M-001 vaccine following receipt of two doses; To assess the safety and reactogenicity of a monovalent inactivated influenza A/H7N9 vaccine (A/H7N9 IIV; two doses) administered with or without MF59 adjuvant following immunization with two doses of M-001 vaccine or placebo, and to assess the serum hemagglutination inhibition (HAI) antibody responses to the A/H7N9 IIV virus after receipt of the first and second dose of MF59 adjuvanted or non-adjuvanted A/H7N9 IIV when administered to adults following receipt of placebo or two doses of M-001 vaccine.

NCT ID: NCT03028987 Completed - Influenza Clinical Trials

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

Start date: November 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is provide a better understanding of the adaptive immune response to the licensed flu vaccines. The investigators hope the information learned from this study will help identify and describe important factors of influenza immunity especially of or specific proteins associated with the T-cell immune response.

NCT ID: NCT03028974 Active, not recruiting - Influenza Clinical Trials

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

Start date: September 2014
Phase: Phase 4
Study type: Interventional

The purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.

NCT ID: NCT03023709 Terminated - Influenza Clinical Trials

Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)

Start date: September 2015
Phase: Phase 4
Study type: Interventional

The investigators collected blood and lymphoid tissues routinely discarded during surgery from adults after a routine seasonal influenza vaccination to determine how immune memory develops at the actual site of infection, and how immunization may alter this process.

NCT ID: NCT03023683 Completed - Influenza Clinical Trials

Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)

Start date: October 2012
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate and compare the human immune response in epithelial cells of the nasopharyngeal mucosa and in blood to live, attenuated influenza vaccine (LAIV) in adults and in children.

NCT ID: NCT03023553 Completed - Influenza Clinical Trials

The Human Mucosal Immune Responses to Influenza Virus (SLVP026)

Start date: December 2012
Phase: Phase 4
Study type: Interventional

This study will examine the immune responses to the seasonal influenza vaccine in single cells of the nasal passages when compared with cells in circulating blood.

NCT ID: NCT03023176 Completed - Influenza Clinical Trials

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013

Start date: September 2013
Phase: Phase 4
Study type: Interventional

This study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.